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861-3 A Phase I Open-Label Dose Escalation Trial of a 
Monoclonal Antibody Against Tissue Factor (Sunol 
cH36) in Stable Coronary Artery Disease: Results of the 
PROXIMATE-TIMI 27 Trial
David A. Morrow, Rafael F. Sequeira, Tim D. Henry, Lawrence A. Galitz, Howard A. 
Cooper, Benjamin M. Scirica, Graham C. Wong, Hing C. Wong, Carolyn H. McCabe, 
Elliott M. Antman, Brigham & Women's Hospital, Boston, MA
Tissue factor (TF) is a critical participant in the genesis of acute coronary syndromes.
Sunol cH36 is a chimeric monoclonal antibody to TF that blocks binding of factor X to
TF:VIIa. This novel anticoagulant had not yet been tested in humans. METHODS: We
assessed the safety & pharmacokinetics of cH36 in pts with stable CAD receiving aspirin.
The safety analysis included all adverse events (AEs) with a focus on bleeding during 7
weeks post-dose. RESULTS: Five doses of cH36 were given IV x1 among 26 subjects
(3-8 per dose tier). Preliminary results show no major bleeding (>2 g/dL fall in Hgb).
Spontaneous minor bleeding exhibited a dose-related pattern (Table). Notably, most
bleeding events were clinically consistent with platelet-mediated bleeding (eg. gum/
tongue). Through expected interaction with a human tissue-factor based assay, cH36
exhibited a dose-related prolongation of the prothrombin time. There were no other lab
abnormalities or rx-related AEs. Human anti-chimeric antibody was not elevated at 7
wks. PK data will also be presented with the final study results. CONCLUSION: In this
initial experience in humans, cH36 exhibited dose-related anticoagulant effects manifest
with minor bleeding. These data support additional study at doses <0.1 mg/kg. We postu-
late that the platelet-mediated bleeding observed with this potent inhibitor of thrombin
generation reflects important networking between thrombin & platelet pathways that may
prove clinically relevant with this novel class of anticoagulants.
4:45 p.m.
861-4 Medullar Neurostimulation Is a Safe Alternative for 
Refractory Angina
Maria M. Irurita, Carlos Culebras, Presentacion Vila, Juncal Irurita, Candida Deniz, Jose 
Fuentes, Maria Teresa Martinez de Saavedra, Isabel Molina, Florentino Sanchez, 
Ricardo Chirino, Vicente Nieto, Insular Hospital, Las Palmas de Gran Canaria, Spain, 
Las Palmas GC University, Las Palmas GC, Spain
Refractory angina defined as severe angina, resistant to maximum medical therapy and
unsuitable for further revascularization. Medullar neurostimulation (MNS), with proved
beneficial effects in a series of chronic painful conditions, could theoretically become a
safe and effective therapeutic alternative.
To assess whether patients with refractory angina (RA), improve their quality of life with-
out increasing morbi-mortality, 34 patients meeting criteria for RA were studied after a
minor surgical procedure to implant a medullar neurostimulator. Consistent with inclusion
criteria, all patients had persistent ischemia, 56% were males, with a mean age of 70 +6
y-o, 97% had hypertension, 81% dyslipidemia, 78% diabetes, 70% peripheral arteriopa-
thy, and 28% chronic renal failure. CHD had lasted 9 +5 years on average, 94% had three
vessels disease and 72% had been previously revascularized. Objective and subjective
clinical and functional variables, including a quality of life scale (Euroquol test) were
assessed at baseline (B) and after 36 months of follow-up (F). Following neurostimulation
both functional classes improved NYHA (3.2 +0.8 B vs. 1.9 +0.8 F; p<0.001) and Cana-
dian (3.5 +0.5 B to 1.7 +0.8 F; p<0.001), angina dropped from 10 to 7 episodes/week
(p<0.001), ejection fraction raised from 36.7 +8.9 to 43.7 +2.5 (p<0.03), and exercise
time increased from 2.2 +1.6 to 4.2 +1.8 minutes (p<0.01). Health brief on mobility (2.19
+0.3 B vs 1.44 +0.5 F), personal care (2.03 +0.6 B vs. 1.11 +0.4 F), daily activity (3.3
+0.5 B vs. 1.4 +0.4 F), chest pain (2.9 +0.2 B vs. 1.3 +0.4 F) and depression/anxiety
parameters (2.7 +0.5 B vs 1.6 +0.5 F), improved by 81% (p<0.001). No differences were
found in body mass index or isotopic perfusion studies when available for comparison (6
patients). Up to 88% has survived 36 months, and for the time being only 5 p have been
hospitalized for cardiac causes (15.6%; p<0.005).
In conclusion, our study shows that in refractory angina, medullar neurostimulation
grants mid-term improvement in quality of life, clinical, and functional parameters. Med-
ullar neurostimulation is an alternative therapy with a small impact on morbility and mor-
tality in selected high risk symptomatic patients.
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869-1 Relationship Between Time to Reperfusion, ST-Segment 
Resolution, Myocardial Blush Scores and Mortality With 
Primary Percutaneous Coronary Intervention for Acute 
Myocardial Infarction: Results From the CADILLAC Trial
Bruce R. Brodie, Costantino Costantini, Eve Aymong, Thomas D. Stuckey, David A. Cox, 
Peter Zimetbaum, Michael McLaughlin, Eulogio Garcia, Mark A. Turco, Roxana Mehran, 
Cindy L. Grines, Alexandra J. Lansky, Gregg W. Stone, LeBauer Cardiovascular 
Research Foundation and Moses Cone Heart and Vascular Center, Greensboro, NC, 
Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, New 
York, NY
Background: Achieving optimum microvascular reperfusion is important for optimizing
outcomes with primary PCI . The relationship between time to reperfusion and measures
of microvascular reperfusion with primary PCI has not been studied.
Methods: The CADILLAC Trial randomized 2,082 pts with AMI to PTCA vs stenting +/-
abciximab. Analyses of myocardial blush (MB) from post-PCI cineangiograms (n=1256)
and ST-segment resolution (STR) from pre and post-PCI ECGs (n=700) were performed
at core laboratories.
Results: Early time to reperfusion (<3 vs 3-6 vs >6 hrs) was associated with a higher fre-
quency of Grade 2-3 MB (55% vs 53% vs 44%, p=0.007) and a higher frequency of com-
plete (>70%) STR (64% vs 68% vs 47%, p=0.0002). Complete STR (>70% vs <70%)
was associated with a higher frequency of Grade 2-3 MB (56% vs 40%, p=0.0007),
although 40% of pts with poor STR had good blush scores and 44% of pts with complete
STR had poor blush scores. One year mortality was lowest with optimum microvascular
reperfusion (complete STR and Grade 2-3 MB) and highest with poor microvascular rep-
erfusion (poor STR and Grade 0-1 MB) (0.6% vs 9.9%, p=0.006). Mortality was excellent
with optimal microvascular reperfusion regardless of time to reperfusion (<3 vs >3 hrs)
(0% vs 1.0%, p=NS), but time to reperfusion did impact mortality in patients with poor
microvascular reperfusion (5.9% vs 11.9%, p=0.54). 
Conclusion: Early time to reperfusion is associated with a greater likelihood of success-
ful microvascular reperfusion after primary PCI. Delayed time to reperfusion negatively
impacts mortality only in patients in whom successful microvascular reperfusion cannot
be restored. While STR and MB are highly correlated, the sizable number of pts with dis-
cordant data suggest that these 2 methods measure different aspects of microvascular
reperfusion. Optimum survival benefit requires achievement of both complete STR and
Grade 2-3 MB.
8:45 a.m.
869-2 Impact of Intravenous Beta-Blockade During Primary 
Percutaneous Intervention on Convalescent Left 
Ventricular Function
Amir Halkin, Cindy L. Grines, David A. Cox, Eulogio Garcia, Roxana Mehran, James E. 
Tcheng, John J. Griffin, Giulio Guagliumi, Bruce Brodie, Mark Turco, Barry D. Rutherford, 
Eve A. Aymong, Alexandra J. Lansky, Gregg W. Stone, The Cardiovascular Research 
Foundation, New York, NY
Background: We have shown that intravenous (IV) beta-blockers (BB) administration dur-
ing primary percutaneous intervention (PCI) imparts a survival benefit, an effect limited to
patients not on chronic oral β-blockade. Whether periprocedural IV BB also improve myo-
cardial recovery is unknown. Methods and Results: In the CADILLAC trial, 2,082 patients
with AMI were randomized to either stenting or angioplasty, +abciximab. IV BB were used
in 1,136 patients (54.5%, BB+), and not in the remaining 946 patients (45.5%, BB-).
Paired left ventriculograms were available at baseline and at 7-month follow-up in 230
and 233 BB+ and BB- patients, respectively.
Baseline LVEF was lower in BB+ patients, though follow-up LVEF was similar in both
groups corresponding to a significantly greater incremental improvement in LVEF in the
BB+ group (Figure). The increase in LVEF from baseline to follow-up in BB+ group was
most pronounced in patients not taking oral BB prior to admission. In patients maintained
on BB prior to admission, the change in LVEF was similar in BB+ and BB- patients.
By multivariate analysis, IV BB in patients not receiving oral BB prior to admission was an
independent predictor of greater increase in LVEF from baseline to 7-month follow-up (β
coefficient=3.24, p<0.0001).
Conclusions. In patients undergoing catheter-based reperfusion for myocardial infarction,
Dose Sunol cH36 (mg/kg)
0.03 0.06 0.08 0.10 0.30
Enrolled (N) 8 4 4 7 3
Major Bleeding (subjects) 0 0 0 0 0
Spont. Minor Bleeding (subjects) 0 1 1 4 3
  Gum/tongue bleeding 0 0 1 2 3
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IV BB treatment is associated with enhanced long-term recovery of LVEF, an effect con-
fined to patients previously not using oral beta-blockers.
9:00 a.m.
869-3 Aqueous Oxygen Therapy for ST Segment Elevation 
Myocardial Infarction: AMIHOT Trial Safety Report and 
Enrollment Completion
Jack L. Martin, Francis Day, Simon Dixon, Douwe Atsma, Pranobe Oemrawsingh, 
Catherine Pensyl, Barbara Lindsay, Antonio Bartorelli, William O'Neill, Main Line Health 
System, Bryn Mawr, PA, William Beaumont Hospital, Royal Oak, MI
Background: Although rapid coronary reperfusion in ST segment elevation myocardial
infarction (STEMI) improves left ventricular function and mortality, epicardial vessel
patency does not fully ensure nutrient flow at the tissue level. Animal and Phase I human
testing of the TherOx® Aqueous Oxygen (AO) System (TherOx Inc., Irvine, California)
suggests that percutaneous coronary infusion of autologous blood mixed with hyperox-
emic saline may help overcome the downstream barrier to oxygen delivery in ischemic
zones and improve myocardial salvage following percutaneous intervention for STEMI.
Methods: A Phase II randomized international trial is designed to evaluate the efficacy of
regional AO therapy in STEMI.A sub-selective catheter positioned in the infarct artery
delivers AO for 90 minutes at 75 ml/minute. Contrast echocardiography performed follow-
ing intervention and before randomization is repeated at 24 hours, and days 30 and 90.
Resting SPECT myocardial perfusion scans are obtained day 14. Primary endpoints
include regional wall motion scores, SPECT perfusion defects, and ST segment resolu-
tion.
Results: Two hundred patients have been randomized after 20 run-in cases. None of the
100 patients assigned to treatment experienced hemodynamic or electrophysiologic
instability during infusion. Repeat angiography when performed following AO therapy
documented perfusion catheter stability and maintenance of TIMI 3 flow. Planned interim
analysis performed after randomization of the first 200 patients demonstrated no safety
concerns and there were no unanticipated major cardiac events. Enrollment of the 270
patient cohort is to be completed by January, 2003.
Conclusion: Preliminary results suggest that regional hyperoxemic therapy appears to
be safe and can be readily applied in institutions performing primary angioplasty for
STEMI. Conclusions regarding the promise of this new therapeutic modality to improve
recovery of left ventricular function requires longer-term follow up.
9:15 a.m.
869-4 Sex Disparities in the Treatment of Non–ST-Segment 
Elevation Acute Coronary Syndromes
Andra L. Blomkalns, L. Kristin Newby, Anita Chen, Eric D. Peterson, Kelly Trynosky, 
Deborah Diercks, William E. Boden, Matthew T. Roe, E. Magnus Ohman, W. Brian Gibler, 
Judith S. Hochman, University of Cincinnati, Cincinnati, OH, Duke Clinical Research 
Institute, Durham, NC
Background: No large-scale examination of sex disparities in the management of acute
coronary syndromes (ACS) has been done since publication of the revised ACC/AHA
Guidelines for the Diagnosis and Treatment of non–ST-elevation acute coronary syn-
dromes (NSTE ACS).
Methods: We conducted a retrospective data analysis from the CRUSADE Initiative,
which enrolls US pts with NSTE ACS (ST-segment depression or transient elevation or
positive cardiac markers). We examined sex differences in the use of acute and dis-
charge medications, in-hospital procedures, discharge interventions, and in-hospital out-
comes.
Results: Of the 35,835 pts (41% women) in the study, women were older and had more
diabetes and hypertension but less prior MI or revascularization (Table). Women less
often received acute aspirin, heparin, GP IIb-IIIa or ACE inhibitors. Discharge treatments
were similarly disparate for use of aspirin, beta blockers, ACE inhibitors, and statins.
Women were at higher risk for death (5.6% vs 4.3%, p<0.0001), post-admission MI (4.0%
vs 3.5%, p=0.03), CHF (12.1% vs 8.8%, p<0.0001), stroke (1.1% vs 0.8%, p<0.003), and
RBC transfusion (17.2% vs 13.2%, p<0.01).
Conclusion: Despite having higher-risk characteristics at presentation and greater in-
hospital risk, women with NSTE ACS are consistently treated less aggressively than
men. Lower use of evidence-based therapies was observed in women even after adjust-
ing for important differences between groups.
9:30 a.m.
869-5 Primary Angioplasty Is More Cost-Effective Than 
Prehospital Thrombolysis for Patients Within 90 
Minutes From a Percutaneous Coronary Intervention 
Center: One-Year Follow-Up of a CAPTIM Substudy
Gerald Vanzetto, Eric Bonnefoy, Helene Bouvaist, Stephanie Marliere, Jean Cassagnes, 
Paul Touboul, Jacques Machecourt, The CAPTIM Study Investigators, University 
Hospital, Grenoble, France
Background: In the CAPTIM study, primary coronary angioplasty (PCA) was as efficient
as pre-hospital thrombolysis (PHT) in patients (pts) with acute myocardial infarction (MI)
within 90 minutes from a coronary intervention (PCI) center. We compared the in-hospital
and 1 year cost-effectiveness of PCA and PHT in a predefined subset of pts from the
CAPTIM study.
Methods: 299 consecutive pts were used for analysis (PCA n=149, PHT n=150, men
80%, mean age=59±12 yrs, anterior wall MI 46%). For each pts, real costs were obtained
for pre-hospital care, key hospital resources, medications, biological and X-rays examina-
tions, catheterization devices, and staff. One year cumulative costs included costs of ini-
tial hospital, plus medications, rehabilitation, examinations, angiographies,
revascularizations and re-hospitalizations occuring after the acute phase.
Results: The 2 groups were similar for baseline data and characteristics of MI. Initial
hospitalization was shorter after PCA than after PHT (9.5 vs. 10.5 days, p=0.009), due to
more frequent emergent or planned angioplasty in the PHT group (42% vs 10%
p<0.001). Median in-hospital real cost were 6097 and 6857 € in the PCA and PHT
respectively (p=0.008). Results at 1 year follow-up (100% completed) are listed bellow.
Conclusion: When compared to PHT, PCA is a dominant strategy for treatment of MI in
pts within 90 minutes of a PCI center, driven by a shorter in-hospital stay and a significant
reduction of non planned revascularizations.
9:45 a.m.
869-6 Beneficial Effects of Combined Thrombolytic Therapy 
and Percutaneous Coronary Angioplasty in Transfer 
Patients With ST Segment Elevation Myocardial 
Infarction: A Report From the American College of 
Cardiology-National Cardiovascular Data Registry
Daniel P. O'Neill, Peter Y. M. Hui, Rupsa R. Yee, Richard Gray, Richard E. Shaw, 
American College of Cardiology - National Cardiovascular Data Registry, Bethesda, MD
Background: Prior studies have compared the efficacy of inter-hospital transport for pri-
mary percutaneous coronary intervention (PCI) versus immediate thrombolysis at a non-
PCI institution in the setting of acute myocardial infarction. The role of thrombolytics prior
to transfer has not been clearly defined and remains controversial. The objective of this
study was to compare outcomes in patients with ST segment elevation MI (STEMI) trans-
ferred with or without thrombolytic therapy for PCI to a referral institution.
Methods: Between January 1, 2001 and March 31, 2003, data on 278,105 PCI proce-
dures were submitted from 304 institutions to the American College of Cardiology
National Cardiovascular Data Registry (ACC-NCDR). Of these, 15,832 involved STEMI
patients transferred for PCI. Thrombolytic therapy was initiated in 8,326 (52.6%) and
7,506 (47.4%) were transferred without thrombolytics. Multiple post-PCI outcomes such
as mortality, emergent surgery and renal failure were analyzed following PCI at the pri-
mary institution. 
Comparison of Treatments
 Women  Men Adjusted OR (95% CI)
Acute Interventions, n (%)
Aspirin 11,960 (89.6) 18,362 (91.6) 0.87 (0.81- 0.93)
Heparin (any) 10,929 (80.0) 16,993 (84.0)  0.92 (0.88-0.98)
Beta blocker 10,007 (75.8) 15,196 (77.7)  0.99 (0.94-1.04)
ACE inhibitor 5,551 (42.4) 8,176 (42.2)  0.95 (0.91-1.00)
GP IIb-IIIa inhibitor 3,574 (28.7) 7,261 (38.6)  0.86 (0.82-0.92)
Procedure Use, n (%)
Diagnostic cath 8,701 (60.1) 15,106 (71.1)  0.86 (0.81-0.91)
PCI 4,516 (31.4) 8,555 (40.4)  0.91 (0.86-0.96)
CABG 1,284 (9.0) 2,941 (14.0)  0.59 (0.54-0.64)
One year cumulative costs (Euros) and events (n,%)
PCA PHT P value
Cardiac death 12 (8.4) 12 (8.2) NS
Recurrence of non fatal MI 7 (4.9) 12 (8.2) NS
Stroke 2 (1.4) 3 (2.0) NS
Death + MI + Stroke (MACEs) 20 (14.0) 24 (16.4) NS
MACEs + unscheduled revascularization 43 (31.8) 85 (61.1) 0.001
Median 1 year cumulative cost /patient 7427 8478 0.04
